XML 42 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Revenues from Contracts with Customers
 12 Months Ended
Jun. 30, 2021
Revenue from Contract with Customer [Abstract]  
Revenues from Contracts with Customers REVENUES FROM CONTRACTS WITH CUSTOMERS
Disaggregation of Revenue from Contracts with Customers—The disaggregation of revenue by segment and product is depicted for the periods presented below, and is consistent with how the Company evaluates its financial performance:

Year Ended June 30,
(in thousands)202120202019
Senior:
Commission revenue:
Medicare advantage$595,132 $285,957 $138,526 
Medicare supplement23,431 34,301 25,118 
Prescription drug plan1,652 2,867 3,209 
Dental, vision, and health15,969 7,758 4,470 
Other commission revenue2,156 362 2,526 
Total commission revenue638,340 331,245 173,849 
Production bonus and other revenue90,361 30,428 18,408 
Total Senior revenue728,701 361,673 192,257 
Life:
Commission revenue:
Core79,666 75,236 76,135 
Final expense78,764 30,592 11,057 
Ancillary4,219 2,036 2,054 
Total commission revenue162,649 107,864 89,246 
Production bonus and other revenue22,854 22,103 21,247 
Total Life revenue185,503 129,967 110,493 
Auto & Home:
Total commission revenue27,621 38,031 33,240 
Production bonus and other revenue3,292 3,158 1,814 
Total Auto & Home revenue30,913 41,189 35,054 
Eliminations:
Total commission revenue(2,004)(534)(335)
Production bonus and other revenue(5,298)(780)— 
Total Elimination revenue(7,302)(1,314)(335)
Total commission revenue826,606 476,606 296,000 
Total production bonus and other revenue111,209 54,909 41,469 
Total revenue$937,815 $531,515 $337,469 

Contract Balances—After a policy is sold, the Company has no material additional or recurring obligations to the policyholder or the insurance carrier. As such, there are no contract liabilities recorded in the consolidated balance sheets. During the year ended June 30, 2020, there was no activity in the contract asset balances other than the movement over time between long-term and short-term commissions receivable and accounts receivable as the policy is renewed, as shown on the balance sheet. A separate roll forward of commissions receivable (current and long term) for the year ended June 30, 2021, is shown below:
(in thousands)2021
Balance as of June 30, 2020$512,961 
Commission revenue from revenue recognized451,086 
Net commission revenue adjustment from change in estimate(6,968)
Amounts recognized as accounts receivable(111,182)
Balance as of June 30, 2021$845,897 

Included in the $7.0 million of net commission revenue adjustments in the table above are increases for contract modifications that occurred during fiscal year 2021, decreases for the reassessment of our transaction prices on each of our cohorts, and increases related to the change in estimate, which modified the method in which we calculate persistency to use policy level persistency to calculate renewal commission revenue.

Production Bonuses and Other—During the year ended June 30, 2021, the Company received advance payments of marketing development funds, which will be amortized over the course of the appropriate fiscal year based on policies sold. As of June 30, 2021, there was an unamortized balance remaining of $3.8 million of fiscal year 2022 marketing development funds recorded in other current liabilities in the consolidated balance sheet.